A new way to care for your furry loved ones!

Around the world, cannabidiol (CBD) continues to gain recognition for its positive effects on health. It’s often chosen to address the  management of anxiety, pain, and inflammation. But what about our furry friends who may also suffer from these conditions, especially with age?

CBD: a natural choice for people and pets

In recent years, medicine has opened up to the possibilities of ingredients from the hemp and cannabis plants, with doctors and patients giving a greater focus to natural therapeutic approaches. Veterinarians are part of this shift and have long sought non-pharmaceutical alternatives that are well-tolerated by pets.

Creso Pharma is at the forefront of this new frontier, most recently introducing Creso’s anibidiol® range - hemp-derived animal complementary feed products that already have been well-embraced by the Swiss market

 

Positive feedback is abundant from both veterinarians and pet owners, including Dr. Fabian Huwiler, who credits anibidiol® with “improving the quality of life of the pet AND the pet owner.” He adds that vets have been waiting for such a product for some time.

anibidiol_8_pack&sachet.jpg

anibidiol® 8 plus

With over 40% of pet owners having considered or tried alternative therapies and herbal remedies, the need for expansion of anibidiol® beyond Switzerland is obvious. Rolf Heeb, Managing Director of Virbac Switzerland says, "…It was the right move and the right time to launch anibidiol®. There has been great interest from both vets and pet owners since its launch."

anibidiol_2.5_pack&sachet.jpg

anibidiol® 2.5 relax

Creso Pharma is happy to announce the launch of the newly formulated complimentary feed products anibidiol® 2.5 regular and anibidiol® 8 plus, enhancing the anibidiol® product range with the aim to even more efficiently support the behavioral balance of the pets and further optimize their relaxation and strengthening of their immune system.

Both products anibidiol® 2.5 regular and anibidiol® 8 plus have been newly formulated, and now contain vitamins in addition to the hemp oil extract.

How anibidiol® delivers

A natural complementary feed for companion animals, anibidiol® is comprised of full spectrum hemp oil extract with CBD and hemp seed oil. The proprietary formula delivers the hemp oil extract, Omega fatty acids, terpenes, flavonoids, and active herbals to enhance an animal’s overall well-being.

anibidiol® is THC-free and  supports the immune system, contributing to balanced behavior, and encourages a general sense of wellness.

“Our experience in the market shows that our veterinary products respond to a real need and have a positive effect on behaviour in pets. In particular, senior dogs and cats benefit enormously as they are more likely to develop behavioural issues due to a combination of health issues and natural ageing issues, including muscle and organ degeneration”. Creso Pharma CEO and Co-Founder Dr. Miri Halperin Wernli.

Innovation from industry leaders

Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world’s 7th largest animal health company with presence in more than 100 countries with more than 4,800 employees and sales subsidiaries in 33 countries. Virbac offers a comprehensive and practical range of products and services covering the majority of species and pathologies.

Through its pharmaceutical expertise and methodical rigor, Creso Pharma strives for the highest quality in its entire range, which includes cannabis- and hemp-derived products and neutraceuticals with wide patient and consumer reach. In addition, Creso retains worldwide rights for a number of proprietary delivery technologies that enhance the bioavailability and absorption of cannabinoids.

This partnership between Virbac and Creso ensures a safe, effective product highlighting the best properties of hemp oil extracts —so our animal friends can enjoy the same benefits and enhanced quality of life we do. Both anibidiol® 2.5 regular and anibidiol® 8 plus have been launched in Switzerland and will be launched in further key countries in Europe and Latin America.